Blog

Governor Eric Holcomb of Indiana has recently enacted a law that earmarks funds for clinical trials to explore the therapeutic effects of psilocybin. This development is part of a broader healthcare legislation that was modified to include provisions on psychedelic research, reflecting a growing interest in the medical potential of such substances. Origins and Goals of the New Measure The additional provisions concerning psychedelics in the healthcare bill originate from a separate proposal by Senator Ed Charbonneau, which was approved by the Senate earlier in February. According to a press release from Charbonneau, the primary aim of the legislation is…

The University of Calgary’s Hotchkiss Brain Institute is poised to launch an innovative clinical trial investigating the use of psilocybin in treating alcohol use disorder (AUD). This trial, involving 128 participants diagnosed with AUD, integrates psychedelic therapy with structured talk-therapy sessions under the guidance of trained therapists. Initiating the Trial with Integrated Psychotherapy The trial will commence with a series of psychotherapy sessions, as disclosed by the principal investigator, Dr. Leah Mayo. Following the initial psychotherapy, participants will receive doses of psilocybin, with the aim to evaluate whether the psychedelic enhances the therapy’s effectiveness. Psilocybin, a psychoactive compound found in…

Depression remains one of the most challenging mental health conditions, affecting millions worldwide with varying degrees of severity. Traditional treatments like psychotherapy and antidepressants are effective for many, yet a subset of patients find these methods inadequate. This has led to a burgeoning interest in alternative treatments, among which ketamine therapy stands out due to its rapid antidepressant effects. The University of Otago is spearheading a groundbreaking trial that seeks to extend the benefits of ketamine therapy, combining it with Behavioural Activation Therapy (BAT) to potentially prolong its efficacy. The Promise of Ketamine as an Antidepressant Ketamine, originally used as…

Toronto, Ontario–(Newsfile Corp. – April 12, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce significant progress in its collaboration with CCrest Laboratories Inc. (“CCrest Labs”), a cGMP-certified pharmaceutical laboratory based in Montreal, which possesses a Controlled Drugs and Substances Dealer’s License and PharmAla…

VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce its intention to complete a non-brokered private placement offering of units of the Company (each, a “Unit”) at a price of $0.18 per Unit for aggregate gross proceeds of up to $750,000 (the “Offering”). It is anticipated that the Offering will be funded solely by a small group of long-term shareholders, known to the…